CAU
EVH icon

Caxton Associates (UK)’s Evolent Health EVH Stock Holding History

Caxton Associates (UK)’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,995
Closed -$93K – 819
2025
Q3 		$93K Buy
+10,995
New +$107K ﹤0.01% 669
2025
Q2 		– Sell
-26,605
Closed -$252K – 752
2025
Q1 		$252K Buy
+26,605
New +$269K 0.01% 666

Other funds holding EVH

CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RF
Rubicon Founders Nashville, Tennessee $138M AUM 61.96% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Caxton Associates (UK)'s EVH Position: Q4 2025 in Review

Caxton Associates (UK) sold out of Evolent Health (EVH) in Q4 2025, closing a stake of 10,995 shares — an estimated $93K sold.

Caxton Associates (UK) first reported a position in EVH in Q1 2025 and held it in 2 quarters. The position peaked at $252K in Q1 2025. 215 funds tracked by Wall St. Rank hold EVH as of Q4 2025.

  • Caxton Associates (UK) reported no remaining Evolent Health position as of Q4 2025 after selling out during the quarter.
  • Caxton Associates (UK) sold 10,995 Evolent Health shares in Q4 2025, an estimated $93K.
  • Caxton Associates (UK) first reported a position in Evolent Health in Q1 2025 and held it in 2 quarters.
  • Caxton Associates (UK)'s Evolent Health position peaked at $252K in Q1 2025.
  • 215 funds tracked by Wall St. Rank held Evolent Health as of Q4 2025.

Based on Caxton Associates (UK)'s 13F filing for Q4 2025, filed 13 Feb 2026.